Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction

Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy. Here we present a patient with chronic myelomonocytic leukemia (CMML) who developed a steroid refractory, post...

Descripción completa

Detalles Bibliográficos
Autores principales: Melody, Megan, Butts, Emily, Menke, David, Landolfo, Kevin, Oken, Keith, Sher, Taimur, Khurana, Sharad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672312/
https://www.ncbi.nlm.nih.gov/pubmed/33240789
http://dx.doi.org/10.1016/j.lrr.2020.100228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672312/
https://www.ncbi.nlm.nih.gov/pubmed/33240789
http://dx.doi.org/10.1016/j.lrr.2020.100228

Ejemplares similares